The ability of semaphorin 3C to promote intratumoral androgen synthesis was confirmed by the authors in castration-resistant prostate cancer patients by conferring continued growth of prostate tumors under androgen deprivation therapy associated with Semaphorin 3C upregulation [109]. The gene discussed is SEMA3C; the disease is prostate carcinoma.